GET DAILY SIGNALSWhy Is Surgery Partners (SGRY) Stock Up +12.93% Today?
Key Takeaways
- Surgery Partners shares surged roughly 12.9% after the company announced an amended merger agreement with HealthSpan Partners that raises the cash buyout price to $25.00 per share.
- The revised deal, up from a prior $23.50 per share, followed receipt of an unsolicited competing proposal of $28.00 per share in cash from an unidentified third party.
- The upgraded transaction values Surgery Partners at an enterprise value of up to approximately $6.0 billion, with potential "ticking fee" payments lifting total consideration to as much as $26.61 per share.
- A strong third-quarter earnings release added further support, reinforcing investor optimism around the company's operating momentum.
- Broader equity markets traded higher during the session, providing a supportive backdrop for risk-on momentum in healthcare names.
- Traders are now watching for the shareholder vote, regulatory clearances, and any further competing bids ahead of the expected first-quarter 2027 closing.
- For more detail on this ticker's Price Targets, Earnings, and Forecast, explore the dedicated pages on Tickeron.
- Discover the strongest AI-driven trading strategies currently available by exploring Trending AI Robots.
Opening Summary
Shares of SGRY, the Brentwood, Tennessee-based operator of ambulatory surgery centers, surgical hospitals, and physician practices, climbed sharply on Monday after the company and HealthSpan Partners announced an amended merger agreement. The stock rose approximately 12.93% to around $26.20, up from the prior session's close of $23.20. The move pushed shares to a new 52-week high and extended a powerful rally that began in late October, when the original acquisition was first announced.
Amended Merger Agreement Drives the Rally
The primary catalyst was the revised buyout, which increases the cash consideration payable to Surgery Partners stockholders from $23.50 to $25.00 per share. The amendment came after the company received an unsolicited, non-binding proposal from an unidentified third party offering $28.00 per share in cash. The upgraded deal values Surgery Partners at an enterprise value of up to roughly $6.0 billion, versus approximately $5.7 billion under the original terms.
The board of directors and its special committee of independent directors unanimously determined that the competing offer did not constitute a superior proposal, citing greater regulatory complexity, a potentially longer timeline to close, and a lack of certain contractual protections. Nevertheless, the rival bid clearly served as leverage, prompting HealthSpan Partners to sweeten its terms and rewarding shareholders with a meaningfully higher price.
Potential "Ticking Fee" Upside
An additional feature of the revised agreement is a "ticking fee" mechanism. If the transaction closes after March 1, 2027, non-Bain Capital stockholders may receive additional monthly cash payments calculated at a 10% annual rate on the $25.00 consideration, up to a maximum of $1.61 per share. That would bring total potential value to $26.61 per share if closing is delayed until the October 23, 2027 outside date. Bain Capital, which owns approximately 39% of outstanding shares, will roll its equity into the acquiring entity rather than receive cash.
Earnings Results Add Support
The session's gains were also underpinned by a better-than-expected third-quarter earnings report. Surgery Partners delivered results that exceeded Wall Street consensus, with revenue and earnings per share coming in ahead of analyst expectations. The earnings-driven move reinforced the view that the company's underlying operations remain healthy even as the go-private transaction moves toward completion.
Market Context and Trading Activity
Trading in SGRY was notably elevated as investors repriced the stock to reflect the higher merger consideration. The price rally pushed shares well above the previous 52-week high and beyond the original $23.50 merger price, signaling growing confidence that the deal will be completed on enhanced terms. Broader U.S. equity indices also advanced during the session, with gains across the major averages providing a supportive macro backdrop for risk appetite in the healthcare sector.
What Comes Next for SGRY
Attention now turns to the mechanics of closing the transaction. The deal remains subject to approval by Surgery Partners stockholders, regulatory clearances, and other customary conditions, with completion still expected in the first quarter of 2027. Risks include the possibility of further competing proposals, regulatory delays, or shareholder dissent. Until the transaction closes, the stock is likely to trade in close proximity to the merger consideration, with movements driven primarily by deal-related developments rather than operating fundamentals.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, and these bots vary by strategy, timeframe, performance metrics, and traded symbols. The Trending AI Robots section highlights only those strategies demonstrating standout performance, helping traders identify approaches that are currently resonating with the market. Explore the page to see which AI-driven strategies are leading right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SGRY's Stochastic Oscillator is staying in overbought zone for 17 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SGRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
SGRY broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on SGRY as a result. In 65 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for SGRY just turned positive on October 12, 2026. Looking at past instances where SGRY's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
SGRY moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SGRY crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 56%.
The 50-day moving average for SGRY moved above the 200-day moving average on October 27, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +0.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where SGRY advanced for three days, in 192 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 120 of 170 cases where SGRY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SGRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.818) is normal, around the industry mean (204.532). P/E Ratio (-33.623) is within average values for comparable stocks, (21.572). SGRY's Projected Growth (PEG Ratio) (21.970) is very high in comparison to the industry average of (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.530) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SGRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in health care services
Industry HospitalNursingManagement
Advertisement